Drugs / DHA-piperaquine
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT07060794 | Jun 2026 → Jun 2028 expected | Plasmodium vivax malaria | Menzies School of Health Research | Not yet recruiting | No outcome recorded |
Also used as a comparator or background therapy in 2 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 41 trial | ||||||
| Phase 4 | NCT01350856 Comparator | May 2011 → Apr 2014 | Plasmodium falciparum malaria | University of Oxford | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT01849640 Comparator | Dec 2012 → Dec 2014 | Plasmodium falciparum malaria | David Saunders | Suspended | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DHA-piperaquine | “Artesunate 2 mg/kg/day for 3 days followed by a full course of either artemether-lumefantrine or DHA-piperaquine or artesunate-mefloquine or artesunate-amodiaquine” NCT01350856 ↗ |